Volume 2.15 | Apr 30

Immune Regulation News 2.15, April 30, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

New Engineering Technique Reinforces Immune Cells that Seek and Destroy Cancer, Says Researcher
In what could be a shot in the arm for adoptive immunotherapy, new research shows promise in enhancing and controlling the growth of T cells in living mice and in human cell cultures, potentially overcoming one of the therapy’s drawbacks. [Press release from Stanford University discussing online prepublication in Proceedings of the National Academy of Sciences U S A]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®
 
 
REQUEST A POSTER STEMCELL Technologies Inc
 



SPECIAL FEATURE

Video – EasySep®Pour-off – A Simple and Effective Way to Isolate Cells


SCIENCE NEWS

Caltech Biologists Link Gut Microbial Equilibrium to Inflammatory Bowel Disease
Microbes perched somewhere between harmful pathogens and helpful symbionts offer new insight into the causes of inflammatory bowel disease and colon cancer. [Press release from California Institute of Technology discussing online prepublication in Cell Host & Microbe]

Brain Tumor Growth Linked to Lowered Expression of Hundreds of Immune Function Genes
A new study links progression of a lethal type of brain tumor with reduced expression of more than 600 immune system genes, suggesting how complex the immune response is to the cancer and the resulting difficulty in targeting specific immune system proteins for treatment. [Press release from Ohio State University discussing online prepublication in Neuro-Oncology]

Immune System: Nanotechnology Helps Illuminate How T Cells Are Activated
A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. [Press release from University of Alberta discussing online prepublication in The Journal of Biological Chemistry]

Immune Cells Predict Success of Head and Neck Cancer Treatment: Study
Levels of a key type of immune cell are higher in head and neck cancer patients whose tumors are linked to the human papillomavirus, according to researchers. [University of Michigan Comprehensive Cancer Center Press Release]

NegSelRosetteSep_645x110_v01a 

CURRENT PUBLICATIONS

Sustained Signaling by Canonical Helper T Cell Cytokines Throughout the Reactive Lymph Node
Here researchers assess cytokine signaling during infection by measuring in vivo phosphorylation of intracellular signal transducer and activator of transcription (STAT) proteins. [Nat Immunol]

Toll-Like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease
Toll-like receptors (TLRs) have previously been shown to play critical roles in the activation of innate immunity. Here, researchers describe that T cell expression of TLR2 regulates T helper 17 cell responses. [Immunity]

Genetic Control of Mammalian T Cell Proliferation with Synthetic RNA Regulatory Systems
Here researchers describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T cell proliferation. [Proc Natl Acad Sci U S A]

Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B Cell Malignancies
Researchers investigated whether nonalloreactive tumor-specific human T cells could be generated from peripheral blood mononuclear cells of healthy donors by the combination of CD19 redirection via chimeric antibody receptor expression and subsequent alloanergization by allostimulation and concomitant blockade of CD28-mediated costimulation. [Cancer Res]

A Pathobiont of the Microbiota Balances Host Colonization and Intestinal Inflammation
Here researchers reveal a protective role for the bacterial type VI secretion system (T6SS) of Helicobacter hepaticus, a Gram-negative bacterium of the intestinal microbiota. H. hepaticus mutants with a defective T6SS display increased numbers within intestinal epithelial cells and during intestinal colonization. [Cell Host Microbe]

Dynamic Regulation of CD45 Lateral Mobility by the Spectrin-Ankyrin Cytoskeleton of T Cells
Researchers have examined the lateral mobility of CD45 in resting and activated T lymphocytes using single-particle tracking and found that the receptor has decreased mobility caused by increased cytoskeletal contacts in activated cells. [J Biol Chem]

A Role for the Atopy-Associated Gene PHF11 in T Cell Activation and Viability
Researchers show that plant homeodomain finger protein 11 (PHF11) is abundant in the cytoplasm of T cells and imported into the nucleus of activated T cells. [Immunol Cell Biol]

Epigenetic Mechanisms Regulate MHC and Antigen Processing Molecules in Human Embryonic and Induced Pluripotent Stem Cells

Researchers showed that low levels of mayor histocompatibility complex (MHC) class-I molecules were associated with absent or reduced expression of the transporter associated with antigen processing 1 and tapasin components in human embryonic stem cells and induced pluripotent stem cells, which are involved in the transport and load of peptides. [PLoS ONE]

INDUSTRY NEWS

Lycera Achieves $11 Million Second Tranche in Series A Financing
Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. [Lycera Corp. Press Release]

Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter
Bristol-Myers Squibb posted first quarter 2010 net sales of $4.8 billion, an increase of 11%, or 8% excluding foreign exchange impact, compared to the same period in 2009. [Bristol-Myers Squibb Co. Press Release]

TxCell Announces Positive Preliminary Results from the Phase I/IIa Clinical Trial of OvaSave in Crohn’s Disease
TxCell SA, a French biotechnology company developing autologous cell-based therapies using Type 1 T-regulatory lymphocytes (Tr1) for the treatment of chronic inflammatory and autoimmune diseases, announced positive preliminary results from the ongoing Phase I/IIa clinical trial regarding OvaSave(R), an investigational new drug, in patients with severe and refractory Crohn’s disease. [TxCell SA Press Release]

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of Multiple Sclerosis
Teva Pharmaceutical Industries Ltd. and Active Biotech announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects. [The Wall Street Journal]

POLICY NEWS

Gubernatorial Candidates Talk Ways to Boost Bioscience
Five gubernatorial candidates offered their prescriptions for creating a healthier climate for Minnesota’s biotech industry that included lower taxes, higher government spending, and faith in science over ideology. [Minnesota, United States]

Request for Information (RFI): Priorities for the NIH Adherence Research Network (NOT-OD-10-078) [National Institutes of Health, United States]

Waivers for Conflicts of Interest for the May 7, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Food and Drug Administration, United States]

FDA Announces Draft Revised Guidance on Transparency and Advisory Committees [Food and Drug Administration, United States]

Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members’ Financial Interest Information and Waivers; Availability (Docket No. FDA-2002-D-0094) [Food and Drug Administration, United States]

EVENTS

97th Annual Meeting of the American Association of Immunologists (AAI)
May 7-11, 2010
Baltimore, United States

29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
June 5-9, 2010
London, United Kingdom

Keystone Symposia: Innate Immunity – Mechanisms Linking with Adaptive Immunity (D3)
June 7-12, 2010
Dublin, Ireland

Federation of Clinical Immunology Societies (FOCIS) 2010
June 24-27, 2010
Boston, United States

Frontiers in Immunology Research (FIRN) 2010 International Conference
July 22-26, 2010
Athens, Greece

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Select BioSciences 7th Annual RNAi & miRNA Europe
September 14-15, 2010
Dublin, Ireland

5th International Conference on Gene Regulation in Lymphocyte Development
October 9-14, 2010
Chania, Greece

Autumn Immunology Conference 2010
November 19-22, 2010
Chicago, United States

Cell Symposia: Influenza – Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit 
here to post your career opportunities.



Have we missed an important article or publication in Immune Regulation News? Click here to submit!


Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us